Plain-English translation of NCT06716814 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is a continuation study for people with moderate to severe hemophilia A who have already been taking in an earlier research trial. The study allows you to keep receiving the medication while researchers continue to monitor how well it works and any side effects. This gives you uninterrupted access to the treatment until it becomes available as a regular prescription in your country.
Once a clinical trial ends, patients often have nowhere to turn to continue a medication that's helping them—especially when the drug isn't yet approved for regular use in their country. This study bridges that gap, ensuring people with hemophilia A don't lose access to this treatment while waiting for commercial availability.
You likely qualify if…
You likely don't qualify if…
You would continue receiving your weekly injections of the medication at the same dose you've been taking. You'll have study visits (in person or by phone) approximately every 13 weeks to check on your health, bleeding episodes, and any side effects. The study continues until the medication becomes commercially available in your country or until March 2027, whichever happens first.
AI-generated summary from trial data · Jul 2, 2026 · Not medical advice
Bulgaria
France